BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Epistemonikos ID: 0a81be93a214b3d92541bd96370e9c3427d43a82
First added on: Feb 01, 2025